| **Title** | The expression and regulation of matrix metalloproteinase-3 is critically modulated by *Porphyromonas gingivalis* lipopolysaccharide with heterogeneous lipid A structures in human gingival fibroblasts |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Author(s)** | Herath Mudiyanselage, TDKH; Wang, Y; Seneviratne, CJ; Darveau, RP; Wang, CY; Jin, L |
| **Citation** | BMC Microbiology, 2013, v. 13, p. 73 |
| **Issued Date** | 2013 |
| **URL** | http://hdl.handle.net/10722/183080 |
| **Rights** | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. |
The expression and regulation of matrix metalloproteinase-3 is critically modulated by Porphyromonas gingivalis lipopolysaccharide with heterogeneous lipid A structures in human gingival fibroblasts

Thanuja D K Herath1, Yu Wang2, Chaminda J Seneviratne1, Richard P Darveau3, Cun-Yu Wang4 and Lijian Jin1*

Abstract

Background: Porphyromonas gingivalis lipopolysaccharide (LPS) is a crucial virulence factor strongly associated with chronic periodontitis which is the primary cause of tooth loss in adults. It exhibits remarkable heterogeneity containing tetra-(LPS1435/1449) and penta-(LPS1690) acylated lipid A structures. Human gingival fibroblasts (HGFs) as the main resident cells of human gingiva play a key role in regulating matrix metalloproteinases (MMPs) and contribute to periodontal homeostasis. This study investigated the expression and regulation of MMPs1-3 and tissue inhibitors of MMP-1 (TIMP-1) in HGFs in response to P. gingivalis LPS and E. coli LPS as a reference. The expression of MMPs 1–3 and TIMP-1 was evaluated by real-time PCR and ELISA.

Results: The MMP-3 mRNA and protein were highly upregulated in P. gingivalis LPS1690- and E. coli LPS-treated cells, whereas no induction was observed in P. gingivalis LPS1435/1449- treated cells. On the contrary, the expression of MMP-1 and −2 was not significantly affected by P. gingivalis LPS lipid A heterogeneity. The TIMP-1 mRNA was upregulated in P. gingivalis LPS1435/1449- and E. coli LPS-treated cells. Next, signal transduction pathways involved in P. gingivalis LPS-induced expression of MMP-3 were examined by blocking assays. Blockage of p38 MAPK and ERK significantly inhibited P. gingivalis LPS1690-induced MMP-3 expression in HGFs.

Conclusion: The present findings suggest that the heterogeneous lipid A structures of P. gingivalis LPS differentially modulate the expression of MMP-3 in HGFs, which may play a role in periodontal pathogenesis.

Keywords: Periodontal disease, P. gingivalis LPS, Lipid A heterogeneity, MMPs, Human gingival fibroblasts

Background

Periodontal disease is a bacterially induced and highly common chronic inflammatory condition in humans, and severe periodontal disease (periodontitis) remains the major cause of tooth loss in adult population worldwide [1]. Dysregulated host response to pathogenic plaque biofilm critically contributes to destructive inflammation resulting in tissue damage and alveolar bone loss [2]. Porphyromonas gingivalis is a keystone periodontal pathogen in the mixed microbial community and it releases copious amount of lipopolysaccharide (LPS) which perpetually interacts with host cells, thereby significantly contributing to periodontal pathogenesis [1-4].

LPS is a potent immuno-inflammatory modulator which causes serious complications in host. It is comprised of three major components viz. outermost O-antigen, core oligosaccharide regions and innermost lipid A [3]. Lipid A is the biologically most active component of LPS that imparts the endotoxin activity. Its structure differs widely among Gram-negative bacteria species depending on the differences in composition.
of attached fatty acids, number of phosphorylation sites and substituted groups attached to the phosphate residues [3]. The canonical lipid A structure in *Escherichia coli* LPS is a hexa-acylated diphasorylated glucosamine disaccharide. Previous studies have shown that *P. gingivalis* possesses highly heterogeneous lipid A structures containing penta-acylated LPS1690 and tetra-acylated LPS1435/1449 and this structural discrepancy may critically account for contrasting biological activities induced by *P. gingivalis* LPS [3,4].

Human gingival fibroblasts (HGFs) are the major cell type in human gingiva [5-7]. They play a key role in maintenance and remodeling of extra cellular matrix (ECM) by producing various structural components, such as collagen, elastin, glycoprotein and glycosaminoglycans. In addition, HGFs also synthesize and secrete various members of matrix metalloproteinases (MMPs) in response to *P. gingivalis* LPS challenge, which ultimately contribute to periodontal tissue destruction [8]. MMPs are a family of structurally and functionally related proteolytic enzymes containing a zinc-binding catalytic domain and they are active against the components of ECM [8-10]. The activity of MMPs is largely regulated by several naturally occurring inhibitors like tissue inhibitors of metalloproteinases (TIMPs) [11]. Overall, there is a remarkable balance between MMPs and TIMPs in periodontal connective tissues and disturbance of this balance is therefore critically implicated in the destruction of periodontal tissues [12,13]. In normal conditions, MMPs are involved in the remodeling and turnover of periodontal tissues under the strict control of TIMPs, which bind specifically to the active site of the enzyme thereby maintaining the equilibrium between degradation and regeneration of ECM [8,14]. Increased production of MMPs 1–3 is observed in chronic inflammatory condition such as periodontitis that results in excessive connective tissue breakdown [14,15]. MMPs such as MMP-1, -2, -3, -9 and -13 are synthesized in periodontal tissues in response to periodontopathic bacteria like *P. gingivalis*. Previous studies have suggested that LPS could regulate the MMP expression in various host cell types including HGFs [10,16].

Currently, there are no studies on the role of *P. gingivalis* LPS lipid A heterogeneity with respect to expression of MMPs in HGFs. The present study therefore aimed to investigate the expression and regulation of MMPs 1–3 and TIMP-1 in HGFs in response to the different isoforms of *P. gingivalis* LPS1435/1449 and *P. gingivalis* LPS1690 as well as *E. coli* LPS as a reference. This study sheds light on the regulation of MMP expression and underlying signal transduction pathways in HGFs in response to heterogeneous *P. gingivalis* LPS, which could have important implications in the pathogenesis of periodontal disease.

### Results

**Heterogeneous *P. gingivalis* LPS lipid A structures differentially modulate MMPs 1–3 and TIMP-1 mRNAs**

The dose-dependent experiments showed that both *P. gingivalis* LPS1435/1449 and LPS1690 differentially modulated the expression of MMP-3 transcript. The latter (0.1-10 μg/ml) markedly upregulated the expression of MMP-3 mRNA while the former did not affect the expression (Figure 1c). Similarly, *E. coli* LPS (0.1-10 μg/ml) significantly upregulated MMP-3 expression. Both isoforms of *P. gingivalis* LPS upregulated to different extent the expression of MMP-1 and MMP-2 mRNAs, while *E. coli* LPS significantly upregulated the expression of these transcripts (Figures 1a and b). TIMP-1 mRNA expression was significantly induced in *P. gingivalis* LPS1435/1449 and *E. coli* LPS-treated cells, and no significant induction was observed following *P. gingivalis* LPS1690 stimulation (Figure 1d).

Notably, MMP-3 transcript was differentially expressed in the cells treated by the two isoforms of *P. gingivalis* LPS. *P. gingivalis* LPS1690 significantly upregulated MMP-3 mRNA expression at 24 and 48 h, while *E. coli* LPS showed prompt expression at 12 h (Figure 2c). MMP-2 mRNA was significantly upregulated by both *P. gingivalis* LPS1435/1449 and LPS1690 at 48 h (Figure 2b), and MMP-1 transcript was significantly upregulated by *P. gingivalis* LPS1690 (Figure 2a). *E. coli* LPS significantly upregulated both MMP-1 and MMP-2 mRNA expression. TIMP-1 transcript was differently modulated by *P. gingivalis* LPS1435/1449 and LPS1690. The former significantly upregulated its expression at 24 and 48 h, so did *E. coli* LPS at 48 h.

**P. gingivalis** LPS1690 significantly upregulates MMP-3 protein expression

Both dose- and time-dependent experiments showed that MMP-3 protein was differentially modulated by *P. gingivalis* LPS1435/1449 and LPS1690 in consistent with its transcript expression profile (Figure 3). *P. gingivalis* LPS1690 at 1 μg/ml and 10 μg/ml significantly upregulated MMP-3 protein expression in a time-dependent manner (12–48 h) (Figure 3c). The MMP-3 level detected in the culture supernatant was greatly higher than that in the cellular fraction (Figures 3a and b). Similar observations occurred in *E. coli* LPS-treated cells. Moreover, the MMP-3 level induced by *P. gingivalis* LPS1690 was significantly greater than that stimulated by *P. gingivalis* LPS1435/1449 (Figures 3a-c).

Next, western blot analysis confirmed that MMP-3 protein markedly increased in *P. gingivalis* LPS1690 and *E. coli* LPS-treated cells at 48 h, while *P. gingivalis* LPS1435/1449 did not induce MMP-3 at a notable level (Figures 4a and c).
The MMP-2 protein expression is not significantly affected by \textit{P. gingivalis} LPS and \textit{E. coli} LPS

Basal expression of MMP-2 was observed at 24 h, and increased at 48 h (Figures 4 and 5). With reference to the control, \textit{P. gingivalis} LPS and \textit{E. coli} LPS did not significantly affect the expression levels of MMP-2 proteins (Figures 4a and b). Gelatin zymograms revealed that the MMP-2 presented in two forms including pro-MMP-2 (72 kDa) and active-MMP-2 (68 kDa). In both culture supernatant (Figure 5a and b) and cellular fraction (Figure 5c and d), the activity of MMP-2 at 24 and 48 h was not significantly affected by \textit{P. gingivalis} LPS and \textit{E. coli} LPS.

\textit{P. gingivalis} LPS\textsubscript{1690} induces MMP-3 expression via MAPK signaling pathway

Blocking assays were performed to elucidate the involvement of NF-\kappa B and MAPK signaling pathways of \textit{P. gingivalis} LPS\textsubscript{1690} induced MMP-3 expression in HGFs. Both ERK inhibitor (U1026) and p38 MAPK inhibitor (SB202190) significantly suppressed the expression levels of MMP-3 transcript (Figure 6a) and protein (Figure 6b) in \textit{P. gingivalis} LPS\textsubscript{1690} and \textit{E. coli} LPS-treated cells. Notably, U1026 inhibited MMP-3 expression to a greater extent with reference to SB202190. The expression of MMP-3 was not significantly reduced by IKK-2 inhibitor IV in \textit{P. gingivalis} LPS\textsubscript{1690}-treated cells, whereas it significantly suppressed MMP-3 in \textit{E. coli} LPS-treated cells (Figure 6).

\textbf{Discussion}

Periodontal disease is a complex inflammatory disease initiated by pathogenic plaque biofilms and results in destruction of tooth-supporting tissues and alveolar bone [17,18]. Proteolytic enzymes like MMPs play a major role in the degradation of collagens in periodontal tissues. The expression and regulation of MMPs and TIMPs in HGFs are therefore crucial for maintenance of tissue homeostasis and periodontal health. Although many studies have been performed to elucidate the mechanisms involved in the synthesis and regulation of MMPs in periodontal research, no studies are available
on the effect of *P. gingivalis* LPS structural heterogeneity on the expression of MMPs and the underlying regulatory mechanisms.

MMP-3 is known as stromelysin which has both elastinolytic and collagenolytic activities that degrade basement membrane components such as laminin, elastin fibronectin as well as collagen types II, III, IV, V, IX, X and XI [8,19]. Its level could significantly increase following the stimuli of pro-inflammatory cytokines, growth factors and LPS [14,20-22]. It has been shown that HGFs could upregulate the expression of MMP-3 due to the effects of pro-inflammatory cytokines such as IL-1β and TNF-α [23-25]. The current study showed that the expression of MMP-3 mRNA and protein was markedly upregulated by *P. gingivalis* LPS, whereas no induction was observed in cells treated with *P. gingivalis* LPS, indicating that the heterogeneous lipid A structures of *P. gingivalis* LPS may differentially modulate the expression of MMP-3 in HGFs. Moreover, TIMP-1 expression was differently modulated by the two isoforms of *P. gingivalis* LPS as well. It functions as an inhibitor of MMPs by forming non-covalent complexes with MMPs. It has recently been shown that MMP-3 and TIMP-1 variants may significantly contribute to chronic periodontitis and disease progression [26]. The imbalance between MMPs and TIMPs has been implicated in periodontal tissue destruction [27].

*P. gingivalis* has long been recognized as a major periodontopathogen [28]. Recently, it is regarded as a keystone pathogen due to its ability to significantly influence the oral microbial community by modulating the innate host response [29,30]. Moreover, this bacterium adopts multiple pathogenic mechanisms to evade or subvert the host immune system [31-33]. Notably, *P. gingivalis* LPS exhibits significant structural heterogeneity with both isoforms of LPS and LPS, and our recent studies show that they differentially affect the innate host defense and underlying signaling pathways, thereby contributing to the pathogenesis of periodontal disease [4,34,35]. The current observation that the different isoforms of *P. gingivalis* LPS modulate the expression of MMP-3 and TIMP-1 may represent an...
additional pathogenic mechanism adopted by this noxious species to disturb the physiological tissue remodeling and tissue homeostasis, leading to the initiation of periodontal disease.

_P. gingivalis_ and its virulence attributes such as LPS can stimulate various cell types to secrete MMPs including MMP-3 [36,37]. On the contrary, some studies have suggested that _P. gingivalis_ LPS may not induce MMPs such as MMP-1, -2 and -9 [38]. A study performed on gingival epithelial cells using _P. gingivalis_ LPS and _E. coli_ LPS showed that neither LPS nor IL-1β induced MMP-2 or MMP-9 [39]. Studies on tissue models such as synovial membranes dissected from rat knee joints showed induction of MMP-1, -3 and -9 mRNA levels but not MMP-2 in response to LPS stimulation [40]. However, foregoing studies have not considered the heterogeneous nature of bacterial LPS lipid A structures. Therefore, the conflicting findings of the previous studies could to some extent be due to different isoforms of _P. gingivalis_ LPS as demonstrated in the present study.

In the present study, _E. coli_ LPS-treated HGFs exhibited rapid and significant induction of MMPs 1 and 2 mRNAs with reference to the cells treated with _P. gingivalis_ LPS. One possibility for this observation may be the higher responsiveness of HGFs to hexa-acylated nature of the _E. coli_ LPS as compared to the penta-acylated structure of _P. gingivalis_ LPS. This notion is consistent with previous findings that _E. coli_ LPS is a potent inducer of the production of MMPs in fibroblast-like synovial cells and rat chondrocytes, as well as other innate host response molecules in HGFs and gingival/oral epithelia [41,42]. Moreover, it was noted that both _P. gingivalis_ LPS1435/1449 and _E. coli_ LPS significantly upregulated the expression of MMP-2 mRNA but not its protein as compared to the controls. A number of factors may account for this finding, such as the stability of mRNA, its processing and splicing patterns, half-life of the target protein and post-translational modifications [43,44]. Therefore, in the present study increase in MMP-2 mRNA expression level may not be necessarily reflected at its protein level.

TIMPs exhibit high affinity for binding with MMPs and lead to inhibition of their activities. In the present study, TIMP-1 mRNA was upregulated by _P. gingivalis_ LPS1435/1449-treated HGFs, while no significant upregulation was observed in _P. gingivalis_ LPS1690-stimulated cells. The current results may not be comparable with previous studies in which the structural heterogeneity of LPS was not fully considered [45-49]. This omission may account for the conflicting reports in the literature. Hence, some studies have observed lower TIMP-1 levels in the conditioned media of HGFs in...
response to *P. gingivalis* LPS [49]. In contrast, other studies have noted the increased expression level of TIMP-1 in gingival crevicular fluid of periodontitis patients [45,47]. Moreover, periodontal treatment could alter the balance between MMP-3 and TIMP-1 [46,48]. Based upon the current findings, further study may be warranted to explore the association of different isoforms of *P. gingivalis* LPS with periodontal conditions in periodontal patients and the possible effect of periodontal treatment on the expression of these LPS isoforms by *P. gingivalis*. In addition, the discrepancy observed in TIMP-1 mRNA and protein expression following the stimulation of both *P. gingivalis* LPS1435/1449 and *E. coli* LPS in HGFs could be due to the complex regulation of transcription and translation [43,44].

LPS is the major immuno-stimulatory component of *P. gingivalis* which has shown to be capable of interacting with TLRs. Binding of LPS to TLRs activates the downstream signal transduction pathways such as NF-κB and MAPK [50,51]. Previous studies have suggested that the activation of MMPs could be through both NF-κB and MAPK signaling [23,52-54]. The present study demonstrated that p38 MAPK and ERK are critically involved in *P. gingivalis* LPS1690- and *E. coli* LPS-induced expression of MMP-3 in HGFs. This finding is supported by a previous study that p38 MAPK and ERK1/2 pathways are essential for the expression and regulation of MMPs in various cell types in response to LPS [54]. ERK, JNK and p38 MAPK pathways play vital roles in regulating the expression of MMPs induced by various stimulants such as cytokines [53,55,56]. It is noteworthy that the nature of the stimuli could result in specific signal transduction pathway in the same cell type. For instance, MAPK inhibitor significantly reduced the MMP-3 production in HGFs stimulated with IL-1β, but not with epidermal growth factor [23]. In addition, NF-κB pathway may be involved in regulation of MMP-3 expression in rabbit dermal fibroblasts, human saphenous vein and rabbit aortic smooth muscle cells [57,58].

The present study showed that NF-κB signaling is not
critically involved in LPS-induced MMP-3 expression in HGFs. Notably, the MAPK pathway but not NF-κB was significantly involved in the regulation of MMP-3 expression in HGFs in both mRNA and protein levels. Previous studies have also proven that the expression of MMP-3 is mainly mediated through P38 MAPK, ERK and tyrosine kinase pathways, but not through NF-κB pathway [23,59,60]. Moreover, although a study reported that the activation of NF-κB could be important for MMP-3 secretion, no consensus NF-κB binding site was identified in the MMP-3 gene promoter [61,62]. It suggests that NF-κB may regulate the expression of this gene through different binding sites or interacting with other transcription factors [59]. Therefore, within the context and limitations of the present study, it is tempting to speculate that MAPK pathway may be crucial for MMP-3 expression in HGFs in response to P. gingivalis LPS. Furthermore, it would be interesting to extend the study to other cells types in human gingiva like gingival epithelial cells to ascertain whether MAPK pathway plays a predominant role in the expression and regulation of MMP-3 in other cells of oral tissues.

Conclusions

The present study reveals that HGFs significantly express MMP-3 in response to penta-acylated P. gingivalis LPS1690 and hexa-acylated E. coli LPS, but not to the tetra-acylated P. gingivalis LPS1435/1449 in HGFs. Blocking p38 MAPK and ERK pathways significantly down-regulates P. gingivalis LPS1690- and E. coli LPS-induced expression of MMP-3. These findings indicate that the heterogeneous lipid A structures of P. gingivalis LPS differentially modulate the expression of MMP-3 in HGFs, which may play a role in periodontal pathogenesis.

Methods

Preparation, purification and identification of P. gingivalis LPS

P. gingivalis LPS was isolated from P. gingivalis ATCC 33277 (the American Type Culture Collection, Rockville,
MD). LPS was prepared by the cold MgCl₂-Ethanol procedure followed by lipid extraction and conversion to sodium salts as previously described [63,64]. Optical densities were measured at 280 nm and 260 nm to verify the nucleic acid and protein contamination. LPS preparations were further treated to remove the endotoxin protein and the final protein contamination was less than 0.1% [65]. The fatty acid composition of \textit{P. gingivalis} LPS was further analysed by Gas chromatographic-mass spectroscopy. Then two separate extractions of \textit{P. gingivalis} LPS with tetra- (LPS₁₄₃₅₁₄₄₉) and penta-acylated (LPS₁₆₉₀) lipid A structures were generated, and their structures were verified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. The canonical hexa-acylated LPS of \textit{Escherichia coli} JM 83-wild type strain was used as the reference [66].

Cell culture
HGFs were obtained from Sciencell research laboratories (Carlsbad, CA, USA) and cultured according to the manufacturer’s instructions [67,68]. Continuous subcultures up to 10th passage contained homogeneous, slim and spindle-shaped cells growing in characteristic swirls. Third to fourth passages of HGFs without any signs of senescence were used for all experiments as described in our previous study [4].

Figure 6 Effects of NF-κB and MAPK inhibitors on \textit{P. gingivalis} LPS₁₆₉₀-induced MMP-3 mRNA (a) and protein (b) expression in HGFs. Cells were pretreated with IKK-2 inhibitor IV (NF-κB inhibitor), SB202190 (p38 MAPK inhibitor) and U1026 (ERK inhibitor) in serum free medium for 1 h, and then treated with \textit{P. gingivalis} (Pg) LPS₁₆₉₀ (1 μg/ml) and \textit{E. coli} LPS (1 μg/ml) for additional 12 h. Total RNA was harvested and MMP-3 mRNA levels were determined by real-time qPCR. Cell culture supernatants were collected and the protein expression level was measured by ELISA. The histogram shows quantitative representations of the MMP-3 mRNA levels of three independent experiments. Each value represents the mean ± SD. *Significant difference (p < 0.05) as compared with the controls. #Significant difference (p < 0.05) as compared with the cells treated with \textit{P. gingivalis} LPS₁₆₉₀ or \textit{E. coli} LPS alone.
Table 1 Nucleotide sequence of real-time qPCR primers

| Primers | Sequence (5’-3’) |
|---------|-----------------|
| MMP1-F  | ATG CTC AAA CCC TGA AGG TG |
| MMP1-R  | CTG CTT GAC CCT CAG AGA CC |
| MMP2-F  | AGG GCA CAT CTT ATG ACA GC |
| MMP2-R  | ATT TGT TGC CCA GGA AAG TG |
| MMP3-F  | GCA GTC TGC TCA GCC TAT CC |
| MMP3-R  | GAG TGT CGG AGT CCA GCT TTC |
| TIMP1-F  | CTG TTT TTG CGT TGG CTG AT |
| TIMP1-R  | TCC GTC CAC AAG CAA TGA GT |
| β-actin -F | AGT GCA ATG AGC GGT T |
| β-actin -R | AGTGAAGGTAGTTCTGCGAT |

Stimulation of HGFs by heterogeneous P. gingivalis LPS

The cells suspended at 10⁵ cell/ml were seeded on six-well-plates and grown until confluent at 37°C with 5% CO₂ in a culture medium for fibroblasts consisting of basal medium with 2% fetal bovine serum, penicillin/streptomycin (0.01% w/v) and fibroblast growth supplement. Once the cells were over 90% confluent, fibroblast medium (FM) was replaced entirely with serum-free medium (FM-acf) for the dose- and time-dependent experiments. In the dose-dependent assay, cells were stimulated with P. gingivalis LPS₃₄₃₅/₄₄₄₉, P. gingivalis LPS₁₆₉₀ or E. coli LPS at 1 µg/ml of LPS was selected as the appropriate dose for the following time-dependent experiments. Cells were incubated with P. gingivalis LPS or E. coli LPS at 1 µg/ml and harvested at 2, 12, 24, and 48 h. Cells without LPS treatment were designated as the controls. Culture supernatants were collected and centrifuged to remove the cellular debris and stored at −70°C for subsequent protein assays. Cellular fraction was then washed with PBS and collected for mRNA and protein extraction.

RNA extraction, cDNA synthesis and real-time qPCR

Total RNA extraction, cDNA transcription and real-time qPCR for MMPs1-3 and TIMP-1 were performed as previously described [17]. In brief, total RNA was extracted from the homogenized HGFs using RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions [35]. cDNA was synthesized by reverse transcriptase-PCR at 43°C for 90 min in a 20 µl of reaction mixture containing 1 µg of total RNA, 1 µl (200 U) of SuperScript™ First-Strand Synthesis System (Invitrogen Corp., Carlsbad, CA, USA), 0.5 µg of oligo dT-primer, first-strand buffer, 10 mM DTT, and 1 mM dNTPs. A control reaction was performed without reverse transcriptase for all samples to verify the absence of genomic DNA contamination. Real-time qPCR was then performed by using the StepOne Real-Time PCR System (Applied Biosystems, Foster City, CA) in at least three separate experiments. Amplification reactions were undertaken in 20 µl of reaction mixture containing 10 µl of Power SYBR® Green PCR Master Mix, 1 µl of cDNA template and 1 µl of each pair of primers for the targeting cytokine genes (Sigma, St. Louis, MO, USA). Real-time primer pairs were designed using ABI software to amplify a sequence that contains two or more exons whenever possible. The amplification efficiencies of the primers used were above 90%. The specific sequences for each pair of primers are listed in Table 1. β-actin was amplified as an internal control. The real-time qPCR reaction conditions were set at 95°C for 10 min followed by 40 cycles at 95°C for 15 s and 60°C for 60 s. The results were analyzed using the comparative cycle threshold (Ct) method as previously described [35]. The expression level of each gene was normalized to a β-actin (ΔΔCt) and the fold changes for each gene were calculated by comparing the test and control samples from the ΔΔCt values.

Total protein extraction and detection of MMP-3 by ELISA

Total proteins were extracted from homogenized HGFs using CellLyte™ MT-mammalian cell lysis extraction reagent (Sigma, USA). Protein concentrations in both of the cell-bound fraction and culture supernatant were measured respectively by BCA protein assay kit (Pierce, Thermo Scientific, USA) according to the manufacturer’s instructions. Enzyme-linked immunosorbent assay (ELISA) was performed to confirm the expression of MMP-3 proteins (BioRad Laboratories, Hercules, CA, USA). The protein expression in both cell lysate and culture supernatants were measured following manufacturer’s instruction with the minimal detectable concentration of 0.009 ng/ml. No cross reactivity or no interference was observed with recombinant MMP-3. The absorbance values were determined by a micro-plate reader (Victor, Vienna, VA, USA) at optical absorbance of 450 nm and the final concentration was determined with reference to a standard curve. Experiments were repeated two times with three biological replicates.

Western blot analysis for MMP-2, -3 and TIMP-1 proteins

Total cell lysates were prepared and 40 µg of cellular extracts were separated by 10% SDS-PAGE gel and subsequently transferred onto a polyvinylidene difluoride membrane (PVDF). The proteins were then blocked against the protein-free blocking buffer (Pierce, Thermo Scientific) for 1 h. Afterwards, membranes were incubated overnight at 4°C with primary antibodies against polyclonal rabbit anti-human IgG; MMP-2 (1:1000; Cell signaling), MMP-3 (1:1000; BioVendor) and TIMP-1 (1:1000; Cell signaling), and incubated with horseradish peroxidase (HRP) conjugated anti-rabbit secondary antibodies.
Visualization of the immunoreactive proteins were accomplished by the use of SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL, USA) and exposed to X-ray films. α-Tubulin was used as the internal loading control (1:10000; Cell Signaling). The detected bands were scanned on a calibrated densitometer, GS-800 and assessed by the imageJ software-based analysis (http://rsb.info.nih.gov/ij/) to quantify the integrated density.

Gelatin zymography for enzymatic activity of MMP-2
SDS-PAGE gelatin zymography was performed to observe the enzymatic activity of MMP-2. Supernatants and cellular proteins were collected from cells grown in serum-free medium at 24 h and 48 h as described above. Centrifugal filter devices (Amicon Ultra-0.5-Millipore USA) with a cut off value of 30000 NMWL (Nominal Molecular Weight Limit) were used to concentrate the supernatants. Culture supernatants or cellular extracts (40 μg) were mixed with 2 x non-reducing sample buffer without β-mercaptoethanol (0.125 M Tris–HCl at pH 6.8, 4% SDS, 20% glycerol and 0.05% bromophenol blue). Proteins were separated by 10% Tris-glycylamide gel copolymerized with 0.1% gelatin as a substrate. After electrophoresis, gels were washed in renaturation buffer (2.5% Triton X-100 in 50 mM Tris–HCl at pH 7.5) for 1 h and incubated for 20 h at 37°C in incubation buffer (0.15 M NaCl, 10 mM CaCl2 and 0.02% Na3 in 50 mM Tris–HCl at pH 7.5). Gels were stained with 5% Coomassie blue and destained with 7% methanol and 5% acetic acid to reveal zones of lysis within the gelatin matrix. Areas of enzymatic activity appeared as clear bands over the dark background.

Signal transduction pathways involved in LPS-induced MMP-3 expression in HGFs
Specific pharmacological inhibitors for NF-κB activity, IKK-β inhibitor (IKK-2 inhibitor IV), p38 MAPK activity (SB202190) and ERK activity (U1026) were used to investigate two major signaling pathways potentially involved in the expression and regulation of MMP-3 in HGFs in response to heterogeneous P. gingivalis LPS. Each inhibitor was first dissolved in dimethyl sulfoxide (DMSO) and diluted in DPBS. Cells were pretreated with kinase inhibitors, including 10 μmol/L of IKK-2 inhibitor IV (Merck, USA), 10 μmol/L of SB202190 (Calbiochem Biosciences Inc, La Jolla, CA, USA) and 15 μmol/L of U1026 (Cell Signaling, USA) respectively for one hour, prior to stimulation with LPS. Afterwards, 1 μg/ml of LPS was added to the medium and cells were incubated for another 12 h. Culture supernatants were collected for analyzing the MMP-3 expression by ELISA. Extracted RNA was subjected to real-time qPCR to detect the MMP-3 transcript expression. Positive controls were the supernatants from the cells treated with LPS alone, whereas the negative controls were incubated with the culture medium alone. In addition, the cells treated with DMSO alone were considered as the vehicle control (data not shown).

Statistical analysis
All experiments were repeated in three assays for real-time qPCR and two assays for ELISA. Results of the experiments were presented as the mean ± SD. The statistical significance of difference between the data sets from the dose-dependent assay was evaluated by student t-test, one-way analysis of variance (ANOVA) and post hoc testing with Bonferroni and LSD methods. Additionally, the repeated-measures of ANOVA were used to determine the differences between data sets from the time-dependent assay. A p-value < 0.05 was considered statistically significant. All statistical analysis was performed using a software program (SPSS 19.0, SPSS Inc, Chicago, IL, USA).

Abbreviations
Pg: P. gingivalis; LPS: Lipopolysaccharides; HGFs: Human gingival fibroblasts; MMPs: Matrix metalloproteinases; TIMP: Tissue inhibitors of metalloproteinases; qPCR: Quantitative PCR; ELISA: Enzyme linked immunosorbent assay; NF-κB: Nuclear factor-kappaB; MAPK: Mitogen-activated protein kinase.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
TDKH, CJS and LJJ conceived the study. RPD carried out the preparation, purification and identification of P. gingivalis LPS. TDKH and CJS performed the cell culture of HGFs, RNA extraction, cDNA synthesis and real-time qPCR, ELISA, Western blot, gelatin zymography, and detection of signal transduction pathways. RPD, CYW, YW and LJ were involved in supervision of the experiments and provided reagents and materials. TDKH, CJS and LJJ analyzed the data, and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors are grateful to Mr. Alan Wong and Ms. Becky Cheung from the Centralized Research Laboratory at the Faculty of Dentistry, The University of Hong Kong, for their technical assistance. This study was financially supported by the Hong Kong Research Grants Council (HKU766909 M, HKU766811 M and HKU767512 M to LJJ) and the Modern Dental Laboratory/ HKU Endowment Fund to LJJ.

Author details
1 Faculty of Dentistry, Periodontology, The University of Hong Kong 34 Hospital Road, Hong Kong SAR, China. 2 Department of Pharmacology and Pharmacy, Faculty of Medicine, The University of Hong Kong Hong Kong SAR, China. 3 School of Dentistry, University of Washington Seattle, WA, USA. 4 School of Dentistry, University of California Los Angeles, CA, USA.

Received: 13 November 2012 Accepted: 15 March 2013
Published: 30 March 2013

References
1. Jin LJ, Armitage GC, Klinge B, Lang NP, Tonetti M, Williams RC. Global oral health inequalities: task group–periodontal disease. Adv Dent Res 2011, 23:221–226.
2. Darveau RP. Periodontitis: a polymicrobial disruption of host homeostasis. Nat Rev Microbiol 2010, 8:461–490.
3. Dixon DR, Danerveu RP: Lipopolysaccharide heterogeneity: innate host responses to bacterial modification of lipid A structure. J Dent Res 2005, 84:584–595.

4. Herath TD, Wang Y, Seneviratne CJ, Lu Q, Danerveu RP, Wang CY, Jin L: Porphyromonas gingivalis lipopolysaccharide lipid A heterogeneity differentially modulates the expression of IL-6 and IL-8 in human gingival fibroblasts. J Clin Periodontol 2011, 38:694–701.

5. Hosokawa I, Hosokawa Y, Ozaki K, Yumoto H, Naaka H, Matsuo T: Proinflammatory effects of muramyldipeptide on human gingival fibroblasts. J Periodontal Res 2010, 45:193–199.

6. Mahonhanda R, Sa-And-Larn N, Monttreekochon P, Pimphukamth A, Yongyanich K, Fukuda MM, Pichyangkul S: IL-8 and IDO expression by human gingival fibroblasts via TLRs. J Immunal 2007, 17B:1151–1157.

7. Phipps RP, Borello MA, Blidren TM: Fibroblast heterogeneity in the periodontium and other tissues. J Periodontal Res 1997, 32:159–165.

8. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA: Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993, 4:197–250.

9. Hanna AR, Perezia JC, Granjeiro JM, Tzjderhane L: The role of matrix metalloproteinases in the oral environment. Acta Odontol Scand 2007, 65:1–13.

10. Sorsa T, Tjaderhane L, Salo T: Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med 2006, 38:306–321.

11. Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000, 1477:267–283.

12. Kubota T, Itagaki M, Hoshino C, Nagata M, Morozumi T, Kobayashi T, Takagi R, Yoshih H: Altered gene expression levels of matrix metalloproteinases and their inhibitors in periodontitis-affected gingival tissue. J Periodontal 2008, 79:166–173.

13. Seguer S, Gogly B, Bédineau A, Coseux G, Brousse N: Is collagen breakdown during periodontitis linked to inflammatory cells and expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gingival tissue? J Periodontal 2001, 72:1398–1406.

14. Sorria T, Tjaderhane L, Salo T: Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis 2004, 10:311–318.

15. Lagente V, Bochat E: Role of matrix metalloproteinases in the inflammatory process of respiratory diseases. J Mol Cell Cardiol 2010, 48:440–444.

16. Agarwal S, Misra R, Agarwal A: Induction of metalloproteinases expression by TLR ligands in human fibroblast like synoviocytes from juvenile idiopathic arthritis patients. Indian J Med Res 2010, 131:771–779.

17. Marsh PD: Dental plaque as a biofilm and a microbial community - implications for health and disease. BMC Oral Health 2005, 6(Suppl 1):S14.

18. Moore WE, Moore LV: The bacteria of periodontal disease. Periodontal 1994, 56:67–77.

19. Kerrigan JJ, Mansell JP, Sandy JR: Matrix metalloproteinases: contribution to disease through the commensal microbiota and complement. Cell Host Microbe 2011, 10:497–506.

20. Danerveu RP, Hajišengallis G, Curtis MA: Porphyromonas gingivalis as a potential community activist for disease. J Dent Res 2012, 91:816–820.

21. Hajišengallis G: Porphyromonas gingivalis-host interactions: open war or intelligent guerilla tactics? Microbes Infect 2005, 7:1657–1665.

22. Lamont RJ, Jenkinson HE. Life below the gum line: pathogenic mechanisms of Porphyromonas gingivalis. Microbiol Mol Biol Rev 1998, 62:1244–1263.

23. Ding PH, Wang CY, Danerveu RP, Jin LJ: Porphyromonas gingivalis LPS stimulates the expression of LPS-binding protein in human oral keratinocytes in vitro. Innate Immun 2013, 19:66–75.

24. Lu Q, Danerveu RP, Samarayake LP, Wang CY, Jin LJ: Differential modulation of human β-defensins expression in human gingival epithelium by Porphyromonas gingivalis lipopolysaccharide with tetra- and penta-acetylated lipid A structures. Innate Immun 2009, 15:325–335.

25. Andrian E, Grenier D, Roubahia M: Porphyromonas gingivalis-epithelial cell interactions in periodontitis. J Dent Res 2006, 85:392–403.

26. You Y, Inaba H, Kato T, Tagashira M, Himm D, Kanda T, Otake Y, Amano M: Inflammatory responses of gingival epithelial cells stimulated with Porphyromonas gingivalis vesicles are inhibited by hop-associated polyphenol. J Periodontal 2008, 79:174–180.

27. Kraus D, Winter J, Jepsen S, Jager A, Meyer R, Deschner J: Interactions of adiponectin and lipopolysaccharide from Porphyromonas gingivalis on human oral epithelial cells. PLoS One 2012, 7:e207016.

28. Andrian E, Grenier D, Roubahia M: Porphyromonas gingivalis lipopolysaccharide induces shedding of syndecan-1 expressed by gingival epithelial cells. J Cell Physiol 2005, 201:178–183.

29. Hyöö A, Oisecka-Iwan A, Niderla-Bielinska J, Moskalewski S: Influence of LPS, TNF, TGF-β1 and IL-4 on the expression of MMPs, TIMPs and selected cytokines in rat synovial membranes incubated in vitro. Int J Mol Med 2011, 27:1217–1237.

30. Fuglberg L, Benni SM, Onnerfjord P, Recklies AD: Proteomic analysis of the LPS-induced stress response in rat chondrocytes reveals induction of innate immune response components in articular cartilage. Matrix Biol 2008, 27:107–118.

31. Santangelo KS, Johnson AL, Ruppert AS, Bertein AL: Effects of hyaluronan treatment on lipopolysaccharide-challenged fibroblast-like synovial cells. Arthritis Res Ther 2007, 9:R1.

32. Catarino JP, Fahy RJ, Flavé EE, Russell ES, Frawley LS: Discordance of prolactin gene transcription, mRNA storage, and hormone release in individual mammatropes. Am J Physiol 1997, 272:E390–E396.

33. Vogel C, Marzette EM: Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet 2012, 13:227–232.

34. Alpagon T, Bell C, Lundtger W, Chambers DW, Rudin R: Longitudinal evaluation of GCF MMP-3 and TIMP-1 levels as prognostic factors for progression of periodontitis. J Clin Periodontol 2001, 28:333–359.

35. Haerin A, Adorjaniak E, Mooney J, Manos A, Knappe DF: Effects of treatment on gingival crevicular collagenase, stromelysin and tissue inhibitor of metalloproteinases and their ability to predict response to treatment. J Clin Periodontol 1996, 23:839–847.

36. Nomura T, Ishii A, Oishi Y, Kohma H, Hara K: Matrix metalloproteinase and tissue inhibitor of metalloproteinase-1. J Clin Periodontol 2001, 29:1011–1015.
49. Zhou J, Windsor LJ: Porphyromonas gingivalis affects host collagen degradation by affecting expression, activation, and inhibition of matrix metalloproteinasises. J Periodont Res 2006, 41:47–54.

50. Kawai T, Akira S: TLR signaling. Semin Immunol 2007, 19:24–32.

51. Takekda K, Akira S: TLR signaling pathways. Semin Immunol 2004, 16:3–9.

52. Cortez DM, Feldman MO, Mummidhi S, Valente AJ, Steffensen B, Vincenti M, Barnes JL, Chandrasekar B: IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK/1/2-dependent C/EBP-beta, NF-kappaB, and AP-1 activation. Am J Physiol Heart Circ Physiol 2007, 293:H356–H365.

53. Gao D, Bing C: Macrophage-induced expression and release of matrix metalloproteinasises 1 and 3 by human periodontocytes is mediated by IL-1beta via activation of MAPK signaling. J Cell Physiol 2011, 226:2869–2880.

54. Lai WC, Zhou M, Shankavaram U, Peng G, Wahl LM: Differential regulation of lipopolysaccharide-induced monocyte matrix metalloproteinasise (MMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. J Immunol 2003, 170:6244–6249.

55. McCawley LJ, Li S, Wattenberg EV, Hudson LG: Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinasise-9 induction and cell migration. J Biol Chem 1999, 274:4347–4353.

56. Reunanen N, Westermarck J, Hakkinen L, Holmstrom TH, Elo I, Eriksson JE, Kahari VM: Enhancement of fibroblast collagenase (matrix metalloproteinasise-1) gene expression by ceramide is mediated by extracellular signal-regulated and stress-activated protein kinase pathways. J Biol Chem 1998, 273:5137–5145.

57. Bond M, Baker AH, Newby AC: Nuclear factor kappaB activity is essential for matrix metalloproteinasise-1 and –3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 1999, 264:561–567.

58. Bond M, Chase AJ, Baker AH, Newby AC: Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinasises-1, -3 and –9 production by vascular smooth muscle cells.Cardiovasc Res2001, 50:556–565.

59. Fukuda K, Fujitsu Y, Kumaigai N, Nishida T: Inhibition of matrix metalloproteinasise-3 synthesis in human conjunctival fibroblasts by interferon-4 or interferon-13. Invest Ophthalmol Vis Sci 2006, 47:2857–2864.

60. Kajanne R, Miettinen P, Mehlem A, Leivonen SK, Birrer M, Foschi M, Kähäri VM, Leppä S: EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J Cell Physiol 2007, 212:489–497.

61. Chase AJ, Bond M, Crook MF, Newby AC: Role of nuclear factor-kappa B activation in metalloproteinasise-1, -3, and –9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler Thromb Vasc Biol 2002, 22:765–771.

62. Frisch SM, Ruley HE: Transcription from the stromelysin promoter is induced by interleukin-1 and repressed by desamethasone. J Biol Chem 1987, 262:16300–16304.

63. Al-Qutub MN, Braham PH, Karimi-Naser LM, Liu X, Genco CA, Darveau RP: Hemin-dependent modulation of the lipid A structure of Porphyromonas gingivalis lipopolysaccharide. Infect Immun 2006, 74:4474–4485.

64. Darveau RP, Pham TT, Lemley K, Reife RA, Bainbridge BW, Coats SR, Howald WN, Way SJ, Hajar AH: Porphyromonas gingivalis lipopolysaccharide contains multiple lipid A species that functionally interact with both toll-like receptors 2 and 4. Infect Immun 2004, 72:5041–5051.

65. Manthey CL, Perera PY, Henricson BE, Hamilton TA, Qureshi N, Vogel SN: Endotoxin-induced early gene expression in C3H/HeJ (Lpsd): macrophages. J Immunol 1994, 153:2635–2643.

66. Bainbridge BW, Coats SR, Pham TT, Reife RA, Darveau RP: Expression of a Porphyromonas gingivalis lipid a palmitoyltransferase in Escherichia coli yields a Chimeric lipid a with altered ability to stimulate interleukin-8 secretion. Cell Microbiol 2006, 8:120–129.

67. Di Domenico G, Del Vecchio L, Postiglione L, Ramaglia L: Immunophenotypic analysis of human gingival fibroblasts and its regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF). Minerva Stomatol 2003, 52:87–91.

68. Poggi P, Rodriguez Y, Barra R, Rizzo S, Rota MT: Mouthrines with alcohol: cytotoxic effects on human gingival fibroblasts in vitro. J Periodontal 2003, 74:623–629.